R&D 5 changes underway for R&D IT shifting to advanced modalitie... Back in 2000, the FDA approved only six biologics versus 27 new molecular entities (NMEs).
News MSD rumoured to be eyeing $3bn+ MoonLake takeover Faced with the looming loss of patent protection for Keytruda, MSD is reported to be interested in buying Swiss immunology player MoonLake.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
